(Reuters) – Merck has cleared a major anti-trust hurdle to its planned $17 billion (11 billion pound) acquisition of Sigma-Aldrich with the latter’s agreed sale of assets to Honeywell , the German drugmaker said on Tuesday.
Merck said U.S. life science company Sigma-Aldrich would sell parts of its solvents and inorganics business in Europe to industrial group Honeywell, which said separately it would pay about 105 million euros ($119 million) for the assets.
“This is another key step towards completing the acquisition of Sigma-Aldrich,” Merck executive board member Bernd Reckmann said in a statement on Tuesday.
Merck said it still expected to close the acquisition of Sigma-Aldrich, its biggest takeover, by the end of November.
The European Commission has to approve the asset sale to Honeywell in order for Merck to close the bigger transaction.
Merck aims to boost its lab-supplies business with the all-cash deal which was agreed more than a year ago.
(Reporting by Georgina Prodhan; editing by Jason Neely)
Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.
Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.
The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).
